Abstract:TNF antagonists may offer therapeutic potential in solid tumors, but patients who have high serum levels of TNF-a fail to respond to infliximab, suggesting consumption of the circulating antibody and loss of transmembrane TNF-a (tmTNF-a) on tumors by ectodomain shedding. Addressing this possibility, we developed a monoclonal antibody (mAb) that binds both full-length tmTNF-a and its N-terminal truncated fragment on the membrane after tmTNF-a processing but does not cross-react with soluble TNF-a. We documented high levels of tmTNF-a expression in primary breast cancers, lower levels in atypical hyperplasia or hyperplasia, but undetectable levels in normal breast tissue, consistent with the notion that tmTNF-a is a potential therapeutic target. Evaluations in vitro and in vivo further supported this assertion. tmTNF-a mAb triggered antibodydependent cell-mediated cytotoxicity against tmTNF-a–expressing cells but not to tmTNF-a–negative cells. In tumor-bearing mice, tmTNF-amAb delayed tumor growth, eliciting complete tumor regressions in some mice. Moreover, tmTNF-amAb inhibitedmetastasis and expression of CD44v6, a prometastaticmolecule. However, the antibody did not activate tmTNF-a–mediated reverse signaling, which facilitates tumor survival and resistance to apoptosis, but instead inhibited NF-kB activation and Bcl-2 expression by decreasing tmTNF-a–positive cells. Overall, our results established that tmTNF-a mAb exerts effective antitumor activities and offers a promising candidate to treat tmTNF-a–positive tumors, particularly in patients that are nonresponders to TNF antagonists. Cancer Res; 73(13); 4061–74. 2013 AACR. Introduction TNF-a exists in 2 bioactive forms: a 26-kD transmembrane form and a 17-kD soluble form that is released after proteolytic cleavage. Both forms of TNF-a display bioactivities via TNF receptors, TNFR I and TNFRII. TNF-a is a 2-edged sword for tumors. On the one hand, there is evidence that it induces tumor necrosis and apoptosis as its name implies. On the other hand, TNF-a is also reported to promote tumor development. Although our and others' previous studies reveal that the ectopic expression of TNF-a at the site of malignancy induces strong and long-term tumor regression (1, 2), increasing evidence indicates that TNF-a functions in promotion and progression of tumors, rather than in protection against tumors, including proliferation, transformation, angiogenesis, invasion, and metastasis in many cancers (3). Knockout of TNF-a or TNFR1 creates mice resistant to chemical carcinogenesis of the skin or liver, respectively (4, 5). Conversely, pretreatment with TNF-a enhances lung metastases (6), and overexpression of TNF-a confers invasive properties on xenograft tumors (7). In the clinic, TNF-a production by tumors is related with a poor prognosis, loss of hormone responsiveness, and cachexia (8, 9). Most studies on TNF-a and tumors refer to the soluble TNF-a (sTNF-a), a typical proinflammatory cytokine; thus, sTNF-a is considered to bridge inflammation and cancer. Although sTNF-a originates from the extracellular sequence of transmembrane TNF-a (tmTNF-a), the bioactivities of both forms of TNF-a are not quite the same. Our previous study shows that tmTNF-a is able to kill some tumor cell lines that are resistant to sTNF-mediated cytotoxicity (10). In contrast, tmTNF-a expressed by tumor cells protects them from apoptosis by inducing constitutive activation of NF-kB via its reverse signaling, as the ectopic expression of the leader sequence of tmTNF-a [namely deletion of the sTNF-a sequence, retaining N-terminal truncated fragment (NTF) including the intracellular part of tmTNF-a] is sufficient to activate NF-kB and render tumor cells resistant to apoptosis induced by sTNF-a (11, 12). Conversely, interruption of the reverse signaling mediated by tmTNF-a increases the sensitivity of tumor cells to sTNF-a–induced cytotoxicity (12). These data suggest that tmTNF-a may influence the opposite actions of sTNF-a, antior protumor. Furthermore, it may be a good tumor surface target for immunotherapy. Authors' Affiliations: Department of Immunology, Tongji Medical College; Department of Hematology, Tongji Hospital, Huazhong University of Science and Technology; and Department of Clinical Laboratory, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China M. Yu and X. Zhou contributed equally to this work. Corresponding Author: Zhuoya Li, Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei 430030, China. Phone: 86-27-83692611; Fax: 86-27-83693500; E-mail: Zhuoyali@mails.tjmu.edu.cn doi: 10.1158/0008-5472.CAN-12-3946 2013 American Association for Cancer Research. Cancer Research www.aacrjournals.org 4061 on May 11, 2014. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Published OnlineFirst June 21, 2013; DOI: 10.1158/0008-5472.CAN-12-3946

Supplementary Figure 2 from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Supplementary Figure 5 from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Supplementary Figure 4 from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Supplementary Figure 6 from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Supplementary Methods from Membrane Versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells

Supplementary Figure 3 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure 6 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Comparison of the cytocidal effect induced by transmembrane and secreted TNF-alpha

Supplementary Figure S2 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Mechanism of Action Differences in the Antitumor Effects of Transmembrane and Secretory Tumor Necrosis Factor-Alpha in Vitro and in Vivo.

Supplementary Figure S4 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Comparison of Antitumor Effects from Transmembrane and Secreted TNF-α in Vivo

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

A Comparison Between the Effects of Trans Membrane and Secretory Tumor Necrosis Factor-Alpha on Tumor Necrosis Factor Receptors

Supplementary Figure Legends from Mir-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma

Supplementary Figure S1 from CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ

Growth Suppresses Breast Cancer α Targeting Transmembrane TNF-Updated

TNF-alpha-induced Growth Suppression of CD34+ Myeloid Leukemic Cell Lines Signals Through TNF Receptor Type I and is Associated with NF-kappa B Activation.